CRISPR-Cas3 Basic Patent Issued in the United States (Patent No. 12371713)

C4U Corporation (“C4U”) has been granted exclusive licenses, including sublicense rights, by the University of Osaka for the inventions related to CRISPR-Cas3, a unique genome editing technology, including the invention titled “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD” 
Based on the above invention, the United States Patent and Trademark Office (USPTO) issued the letter of patent on November 7, 2023 and thereafter, C4U has tried to expand its right in the U.S.
Now, C4U is pleased to announce that the USPTO issued the letter of patent for a divisional patent application of the above invention on July 29, 2025 (Patent No. 12371713). This patent is matured from a divisional application of U.S. Patent No. 11807869 and has an effect as a broader basic patent for the CRISPR-Cas3 system in the United States.

The invention has also been patented in Japan (Patent No. 6480647), and its divisional applications were matured into Patent Nos. 7301332, 7430358 and 7731156. Outside of Japan, in addition to the United States, the invention has also been patented in Eurasia (Patent No. 040859), Korea (Patent No. 10-2541398), China (Patent No. 110770342), Europe (Patent No. 3636753), Australia (Patent No. 2018279457), Mexico (Patent No. 415175), and India (Patent No. 548919). Also, a grant eligibility notice has also been issued in Singapore.
C4U will continue to strengthen its intellectual property portfolio with regard to CRISPR-Cas3 technology worldwide and accelerate its application in a wide range of fields, including pharmaceutical field.

About C4U Corporation
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.　https://www.crispr4u.jp/en/